Related Experiment Video

Updated: Mar 28, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Immune Therapy

Lysanne Lievense1, Joachim Aerts1, Joost Hegmans2

  • 1Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Dr. Molewaterplein 50, Rotterdam, 3015 GD, The Netherlands.

Advances in Experimental Medicine and Biology
|December 16, 2015
PubMed

Insights

Lung cancer, once thought resistant to immunotherapy, is now a promising target. Understanding immune cells in the tumor microenvironment is key to developing effective lung cancer immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Lung cancer was historically considered resistant to immunotherapy.
  • Emerging evidence indicates the presence of anti-tumor immune responses in lung cancer patients.
  • This shifts the paradigm, positioning lung cancer as a viable target for immunotherapeutic strategies.

Purpose of the Study:

  • To explore the role of the tumor microenvironment in lung cancer immunotherapy.
  • To identify and characterize immune cells that influence anti-tumor responses in lung cancer.
  • To establish the prognostic value of these immune cells in lung cancer patients.

Main Methods:

  • Analysis of immune cell populations within the lung cancer tumor microenvironment.
  • Identification of immune cells that promote or suppress anti-tumor immunity.
  • Evaluation of the prognostic significance of identified immune cells.

Main Results:

  • Specific immune cell types facilitating or inhibiting anti-tumor responses have been identified in lung cancer.
  • The prognostic value of these immune cells in lung cancer has been established.
  • This knowledge is driving the development of novel immunotherapeutic strategies.

Conclusions:

  • Lung cancer is emerging as a target for immunotherapy, contrary to previous assumptions.
  • Understanding tumor-infiltrating immune cells is crucial for advancing lung cancer immunotherapy.
  • Ongoing clinical trials are evaluating various immunotherapeutic approaches with promising early results.
Keywords:
Cancer immunotherapyCellular immunotherapyImmunosuppressive cellsMyeloid-derived suppressor cellsPersonalized medicineRegulatory T cellsTumor antigensTumor microenvironmentTumor vaccinesTumor-associated macrophages

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
740
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
664
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
319